UCL spinout Ori Biotech has raised more than $100m in a series B round led by Novalis LifeSciences, just over a year after closing a $30m series A round.
Ori Biotech, a UK-based cell and gene therapy manufacturing technology spinout of University College London, picked up more than $100m in its series B round led by Novalis LifeSciences on Tuesday.
Puhua Capital and Chimera Abu Dhabi also took part in the round, as did returning investors Amadeus Capital Partners, Delin Ventures, Northpond Ventures and Octopus Ventures. The latter four had joined Kindred Capital for a $30m series A round in October 2020.
Founded in 2015, Orin Biotech has built a system to close, automate, digitise and standardise cell and gene therapy manufacturing. It will use the series B capital to move through pre-commercialisation activities and begin offering access to the platform in 2022.
Jason Foster, chief executive of Orin Biotech, said: “Our mission as a company is to enable widespread patient access to life-saving cell and gene therapies.
“One of the biggest obstacles to achieving this is cell…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
